Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk-Mitigation Measure. Pharmacotherapy, 39(1): 40-54.
This website uses cookies to improve your experience. We’ll assume you’re ok with this, but you can opt-out if you wish. [cookie_settings] [cookie_button]
